To celebrate Rare Disease Day, the pharmaceutical company Mereo Biopharma invited Ferre Castrel and Martijn Dillen from Belgium to its headquarters in London to talk about their lives with OI. OIFE Magazine reached out to them to learn about the experience. Hi guys, thanks for doing this interview! Can you briefly introduce yourselves? Ferre: “Hello!…
The Remedi4All consortium & the MOI-A Trial (Losartan) Information provided by Claudia Fuchs, EURORDIS What is Remedi4All? The EU-funded multidisciplinary consortium REMEDi4ALL (Repurposing Medicines for All) has an ambition to establish a European research and innovation eco-system that facilitates fast and cost-effective patient-centric development and implementation of repurposed medicines, meeting high unmet medical needs in…
Interview with Nick Bishop, professor of paediatric bone diseases at the University of Sheffield, UK Who are you and what is your relationship to OI? My name is Nick Bishop and I am professor of paediatric bone diseases at the University of Sheffield in the UK. I’ve worked here for the last 25 years (nearly).…
New conect4children Consortium will include a study on Losartan as a treatment for osteogenesis imperfecta. The conect4children (c4c) consortium announced on April 29th the selection of its first portfolio of pan-European paediatric studies aimed at advancing the understanding of high priority medicines commonly used in babies, children and young people in Europe. The four inaugural…
